Thermo Fisher Scientific CD18 Monoclonal Antibody (WT.3)

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Flow Cytometry (Flow)

1 µg/test

View 3 publications 3 publications

ELISA (ELISA)

-

View 1 publication 1 publication

Immunoprecipitation (IP)

Assay-dependent

-

Product Specifications

Species Reactivity

Rat

Published species

Rat

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

WT.3

Immunogen

Rat beta2 Integrin

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.0 mg/mL

Purification

Protein G

Storage buffer

PBS

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_223590

Product Specific Information

MA1817 targets CD18 in FACS, IP, and WB applications and shows reactivity with Rat samples.

The MA1817 immunogen is rat beta2 Integrin.

MA1817 detects CD18 which has a predicted molecular weight of approximately 83 kDa.

This product is a Low Endotoxin formulation.

This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).

Target Information

CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes. CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling. CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis. Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1). Two transcript variants encoding the CD18 protein have been identified.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.